PMID- 26889256
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220331
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 11
IP  - 1
DP  - 2016 Jan
TI  - Upper gastrointestinal safety and tolerability of oral alendronate: A 
      meta-analysis.
PG  - 289-296
AB  - Osteoporosis (OP), which is a common bone disease associated with reduced bone 
      mineral density and disordered bone microstructure, may result in an increased 
      risk of bone fracture. The present study aimed to investigate the frequency of 
      alendronate (Aln)-associated upper gastrointestinal tract adverse events (GIAEs) 
      in postmenopausal women with OP. The following databases were searched in order 
      to identify relevant studies: Medline (using PubMed as the search engine), 
      Embase, the Web of Science and the Cochrane Central Register of Controlled Trials 
      (up to December 2014). Studies were selected for inclusion if they were 
      randomized, double-blind, placebo-controlled trials, which had investigated the 
      safety of Aln versus a placebo for the treatment of postmenopausal women with OP. 
      The primary outcomes of the included studies were total adverse events (AEs) and 
      upper GIAEs, whereas individual upper GIAEs were considered as secondary 
      outcomes. The general characteristics and outcomes of each study were abstracted 
      by two independent researchers, and Review Manager 5.3 software was used for data 
      syntheses and the meta-analysis. A total of nine studies, including 15,192 
      randomized patients, met the inclusion criteria and contributed to some or all of 
      the meta-analysis outcomes. The Mantel-Haenszel method was used to calculate risk 
      ratios, and their 95% confidence intervals (CI) were determined using either the 
      fixed or random effects model, depending on the level of heterogeneity. The 
      relative risk (95% CI) of AEs associated with Aln treatment, as compared with the 
      placebo group, was 1.01 (0.97-1.06), and the relative risk (95% CI) of 
      discontinued Aln treatment due to AEs was 1.04 (0.91-1.19). In addition, the 
      relative risk (95% CI) of upper GIAEs was 1.02 (0.99-1.06), and the relative risk 
      (95% CI) of discontinued Aln treatment due to upper GIAEs was 1.23 (0.97-56). In 
      addition, these results remained robust to sensitivity analyses. The results of 
      the present study suggested that Aln has a good GI tract tolerability, and that 
      daily treatment with 10 mg Aln sodium does not increase the risk of GIAEs in 
      postmenopausal women with OP.
FAU - Zhou, Manru
AU  - Zhou M
AD  - Department of Pharmacology, Guangdong Medical University, Zhanjiang, Guangdong 
      524023, P.R. China.
FAU - Zheng, Yayuan
AU  - Zheng Y
AD  - Department of Pharmacy, The Affiliated Hospital of Guangdong Medical University, 
      Zhanjiang, Guangdong 524023, P.R. China.
FAU - Li, Jin
AU  - Li J
AD  - Department of Pharmacology, Guangdong Medical University, Zhanjiang, Guangdong 
      524023, P.R. China.
FAU - Wu, Jingkai
AU  - Wu J
AD  - Department of Pharmacology, Guangdong Medical University, Zhanjiang, Guangdong 
      524023, P.R. China.
FAU - Xu, Weiming
AU  - Xu W
AD  - Department of Pharmacology, Guangdong Medical University, Zhanjiang, Guangdong 
      524023, P.R. China.
FAU - Cui, Liao
AU  - Cui L
AD  - Department of Pharmacology, Guangdong Medical University, Zhanjiang, Guangdong 
      524023, P.R. China.
FAU - Yao, Weimin
AU  - Yao W
AD  - Department of Respiratory Medicine, The Affiliated Hospital of Guangdong Medical 
      University, Zhanjiang, Guangdong 524023, P.R. China.
FAU - Liu, Yuyu
AU  - Liu Y
AD  - Department of Pharmacology, Guangdong Medical University, Zhanjiang, Guangdong 
      524023, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20151110
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC4727055
OTO - NOTNLM
OT  - alendronate
OT  - gastrointestinal
OT  - meta-analysis
OT  - osteoporosis
EDAT- 2016/02/19 06:00
MHDA- 2016/02/19 06:01
PMCR- 2015/11/10
CRDT- 2016/02/19 06:00
PHST- 2014/12/30 00:00 [received]
PHST- 2015/09/24 00:00 [accepted]
PHST- 2016/02/19 06:00 [entrez]
PHST- 2016/02/19 06:00 [pubmed]
PHST- 2016/02/19 06:01 [medline]
PHST- 2015/11/10 00:00 [pmc-release]
AID - ETM-0-0-2848 [pii]
AID - 10.3892/etm.2015.2848 [doi]
PST - ppublish
SO  - Exp Ther Med. 2016 Jan;11(1):289-296. doi: 10.3892/etm.2015.2848. Epub 2015 Nov 
      10.